TAT decorated siRNA polyplexes for inhalation delivery in anti-asthma therapy (2023)
Sequence: YGRKKRRQRRR
| Experiment Id | EXP002457 |
|---|---|
| Paper | TAT decorated siRNA polyplexes for inhalation delivery in anti-asthma therapy |
| Peptide | HIV-1 TAT(47–57) |
| Delivery Success Class | no |
| In Vivo Flag | no |
| Uptake Confirmed | yes |
| Label Confidence | high |
| In Vitro Functional Effect | yes |
| Endosomal Escape Evidence | |
| Peptide Concentration | |
| Rna Concentration | 100–200 nM siRNA |
| Mixing Ratio | polymer/siRNA R = 10 |
| Formulation Format | polyplex |
| Formulation Components | PHEA-g-bAPAE-PEG-MLB + siRNA + TAT |
| Size Nm | 120.00 |
| Zeta Mv | 10.00 |
| Model Scope | in_vitro |
| Model Type | in vitro |
| Cell Lines Or Primary Cells | 16-HBE human bronchial epithelial cells |
| Animal Model | |
| Administration Route | |
| Output Type | gene silencing (ELISA) |
| Output Value | Significant IL-8 reduction after LPS stimulation |
| Output Units | |
| Output Notes | TAT enhances uptake and silencing vs non-decorated polyplexes |
| Toxicity Notes | High cytocompatibility |
| Curation Notes |